Erratum: Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: Results from a double-blind, randomized, parallel group study (American Journal of Gastroenterology (2015) 110 (708-715) DOI: 10.1038/ajg.2015.114);Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: Results from a double-blind, randomized, parallel group study

American Journal of Gastroenterology

Volumn 110, Issue 5, 2015, Pages 708-715

  Van Assche, Gert ^a   Manguso, Francesco ^b   Zibellini, Marco ^c   Cabriada Nunõ, José Luis ^d   Goldis, Adrian ^e   Tkachenko, Evgeniy ^f   Varoli, Guido ^c   Kleczkowski, Dariusz ^g   Annese, Vito ^h   D'Heygere, François ⁱ   Balzano, Antonio ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b CARDARELLI HOSPITAL   (Italy)

^c CHIESI FARMACEUTICI S P A   (Italy)

^d HOSPITAL DE GALDAKAO   (Spain)

^e Policlinica Algomed Centru Medical e Gastroenterologie Medicina Interna Si Nefrologie   (Romania)

^f NORTH WESTERN STATE MEDICAL UNIVERSITY NAMED AFTER I I MECHNIKOV   (Russian Federation)

^g Endoskopia Sp Z oo   (Poland)

^h CAREGGI UNIVERSITY HOSPITAL   (Italy)

ⁱ AZ GROENINGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BALSALAZIDE; BECLOMETASONE DIPROPIONATE; HYDROCORTISONE; MESALAZINE; OLSALAZINE; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE; ANTIINFLAMMATORY AGENT; BECLOMETASONE; ENTERIC COATED TABLET;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ACTIVITY INDEX SCORE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GOLD STANDARD; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERIANAL ABSCESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCORING SYSTEM; SIDE EFFECT; TABLET; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; ADOLESCENT; BLOOD; CLINICAL TRIAL; COLITIS, ULCERATIVE; COMPARATIVE STUDY; DRUG ADMINISTRATION; ENTERIC COATED TABLET; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; BECLOMETHASONE; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROCORTISONE; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PREDNISONE; SEVERITY OF ILLNESS INDEX; TABLETS, ENTERIC-COATED; YOUNG ADULT;

EID: 84928924901     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.145     Document Type: Erratum

References (24)

1. Manso G, Baker A, Taylor IK et al. I n vivo and i n vitro effects of glucocorticosteroids on arachidonic acid metabolism and monocyte function in nonasthmatic humans. Eur Respir J 1992 ; 5 : 712-6.
2. Linden M. The effects of beta 2-adrenoceptor agonists and a corticosteroid, budesonide, on the secretion of inflammatory mediators from monocytes. Br J Pharmacol 1992 ; 107 : 156-60.
3. Schmidt J, Fleissner S, Heimann-Weitschat I et al. The effect of different corticosteroids and cyclosporine A on interleukin-4 and intrleukin-5 release from murine TH2-type T cells. Eur J Pharmacol 1994 ; 260 : 247-50.
4. Boobis AR. Comparative physicochemical and pharmacokinetic profi les of inhaled beclometasone dipropionate and budesonide. Respir Med 1998 ; 92 : 2-6.
5. Travis SP, Stange EF, L?ann M et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008 ; 2 : 24-62.
6. Daley-Yates PT, Price AC, Sisson JR et al. Beclometasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001 ; 51 : 400-9.
7. Harris DM. Some properties of beclometasone dipropionate and related steroids in man. Postgrad Med J 1975 ; 51 : 20-5.
8. Steed KP, Hooper G, Ventura P et al. The in vivo behavior of a colonic delivery system. Int J Pharmacol 1994 ; 112 : 199-206
9. Campieri M, Adamo S, Valpiani D et al. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther 2003 ; 17 : 1471-80.
10. Rizzello F, Gionchetti P, D'Arienzo A et al. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebocontrolled study. Aliment Pharmacol Ther 2002 ; 16 : 1109-16.
11. Nunes T, Barreiro-de Acosta M, Nos P et al. RECLICU Study Group of GETECCU. Usefulness of oral beclometasone dipropionate in the treatment of active ulcerative colitis in clinical practice: the RECLICU Study. J Crohns Colitis 2010 ; 4 : 629-36.
12. Romano C, Famiani A, Comito D et al. Oral beclometasone dipropionate in pediatric active ulcerative colitis: a comparison trial with mesalazine. J Pediatr Gastroenterol Nutr 2010 ; 50 : 385-9.
13. Multicentre, double blind randomised, balanced parallel group, controlled, dose range finding study of 5 mg every 2 days, 5 mg, and 10 mg of Beclometasone Dipropionate enteric coated tablets versus placebo in mild to moderate extensive ulcerative colitis patients under oral aminosalicylates (like mesalazine, sulfasalazine) preventive therapy. Clinical Study Report no. RA/PR/1405/001/00. Chiesi Farmaceutici S.p.A. Data on fi le.
14. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987 ; 317 : 1625-9.
15. Rachmilewitz D. Coated mesalazine (5-aminosalicilyc acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 1998 ; 298 : 82-6.
16. Travis SP, Danese S, Kupcinskas L et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014 ; 63 : 433-41.
17. Sandborn WJ, Travis S, Moro L et al. Once-daily budesonide MMX? extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012 ; 143 : 1218-26.
18. Dignass A, Lindsay JO, Sturm A et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012 ; 6 : 991-1030.
19. Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J 1962 ; 2 : 1708-11.
20. Lofberg R, Danielsson A, Suhr O et al. Oral budesonide versus prednisolone in patients withactive extensive and left-sided ulcerative colitis. Gastroenterology 1996 ; 110 : 1713-8.
21. Campieri M, Ferguson A, Doe W et al. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997 ; 41 : 209-14.
22. Rutgeerts P, Lofberg R, Malchow H et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994 ; 331 : 842-5.
23. Meijer RJ, Postma DS, Kerstjens HA. Conventional RIA underestimates cortisol suppression in the presence of prednisolone. Thorax 2002 ; 57 : 374.
24. Manguso F, Bennato R, Lombardi G et al. ECLIA method underestimates cortisol suppression in UC patients treated wiThoral prednisone. World J Gastroenterol 2014 ; 20 : 10895-9.